Predictive Value of Alert Triggers for Identification of Developing Adverse Drug Events : Journal of Patient Safety

Secondary Logo

Journal Logo

Original Articles

Predictive Value of Alert Triggers for Identification of Developing Adverse Drug Events

Moore, Carlton MD, MS*; Li, Jiang BS†; Hung, Chang-Chiao BS‡; Downs, John MD*; Nebeker, Jonathan R. MD, MS§

Author Information
Journal of Patient Safety 5(4):p 223-228, December 2009. | DOI: 10.1097/PTS.0b013e3181bc05e5

Abstract

Objective: 

Adverse drug events (ADEs) are the most common type of iatrogenic injury in hospitalized patients. However; the ability of electronic triggers to identify patients at high risk for inpatient ADEs before they occur has not been well studied. The objective of this study was to assess the positive predictive value of event triggers to detect developing ADEs.

Methods: 

We conducted a prospective observational study in patients at a university-based teaching hospital during a 5-month period. Patients were monitored using electronic triggers designed to detect patients at increased risk for 4 types of ADEs: hypoglycemia, hypokalemia, hyperkalemia, and thrombocytopenia. Each patient for whom a trigger fired was followed to determine whether a drug-induced markedly abnormal laboratory result occurred between 1 and 72 hours after the initial trigger firing.

Results: 

Overall, the triggers fired 611 times on 456 patients. Of the 456 patients, 101 experienced 1 or more related ADEs between 1 and 72 hours after the initial trigger firing. The positive predictive value of the triggers and median time from trigger firing to ADE was 31% and 11.6 hours for hypoglycemia, 4.0% and 17 hours for hypokalemia, 31% and 25.4 hours for hyperkalemia, and 21% and 48.4 hours for thrombocytopenia.

Conclusion: 

Computerized triggers have sufficient predictive value to detect developing ADEs and can help clinicians avert ADEs. More research is required to determine whether real-time, primary-prevention alerts may reduce the incidence of ADEs.

© 2009 Lippincott Williams & Wilkins, Inc.

You can read the full text of this article if you:

Access through Ovid